IJARCCE ISSN (O) 2278-1021, ISSN (P) 2319-5940

International Journal of Advanced Research in Computer and Communication Engineering

Impact Factor 8.102 ⁜ Peer-reviewed & Refereed journal ⁜ Vol. 14, Issue 1, January 2025

DOI: 10.17148/IJARCCE.2025.14107

Artificial Intelligence and Machine Learning Driven Drug Discovery Analysed How Algorithms are Accelerating the Drug Discovery Process and Identifying New Drug Users.

Prof. Shalini V. Rakhade[1], Prof. Vijay M. Rakhade[2],

Rupesh Kohli[3], Anuja Sarangdhar[4],Adway Sawant[5], Sugandhi Patil[6]

Assistant Professor, Pharmacy, YBCP, CHANDRAPUR (M.S), India[1]

Assistant Professor, AIDS, SITRC, Nashik, India[2]

Student, AIDS, SITRC, Nashik, India[3-6]

Abstract: Machine learning models extract patterns from complex datasets, enabling accurate predictions and informed decision-making, thus accelerating drug discovery. Deep learning, specifically convolutional neural networks (CNN), excels in image analysis, aiding biomarker identification and optimizing drug formulation. Natural language processing facilitates the mining and analysis of scientific literature, unlocking valuable insights and information. The future of AI in pharmacological research is promising, with integration with emerging technologies like genomics, proteomics, and metabolomics offering the potential for personalized medicine and targeted therapies. Collaboration among academia, industry, and regulatory bodies is essential for the ethical implementation of AI in drug discovery and development. Continuous research and development in AI techniques and comprehensive training programs will empower scientists and healthcare professionals to fully exploit AI's potential, leading to improved patient outcomes and innovative pharmacological interventions. However, the adoption of AI in pharmacological research raises ethical considerations. Ensuring data privacy and security, addressing algorithm bias and transparency, obtaining informed consent, and maintaining human oversight in decision-making are crucial ethical concerns. The responsible deployment of AI necessitates robust frameworks and regulations. Artificial intelligence (AI) has transformed pharmacological research through machine learning, deep learning, and natural language processing. These advancements have greatly influenced drug discovery, development, and precision medicine. AI algorithms analysed vast biomedical data identifying potential drug targets, predicting efficacy, and optimizing lead compounds. AI has diverse applications in pharmacological research, including target identification, drug repurposing, virtual screening, de novo drug design, toxicity prediction, and personalized medicine. AI improves patient selection, trial design, and real-time data analysis in clinical trials, leading to enhanced safety and efficacy outcomes. Post-marketing surveillance utilizes AI-based systems to monitor adverse events, detect drug interactions, and support pharmacovigilance efforts.

Keywords: Drug discovery, convoluted neural networks, machine learning, pharmacological research, artificial intelligence.

I. INTRODUCTION

Artificial intelligence (AI) is the simulation of human intelligence in machines programmed to think and act like humans. It involves the development of algorithms and computer programs that can perform tasks that typically require human intelligence, such as visual perception, speech recognition, decision-making, and language translation [1]. The field of AI has evolved and expanded, drawing from various academic disciplines such as computer science, mathematics, philosophy, and physics. AI has revolutionized the research landscape across diverse domains, empowering breakthrough discoveries and accelerating progress like never before. This narrative review aimed to contribute to understanding AI's role in pharmacology by providing a comprehensive and critical analysis of the existing body of literature and offering insight into its future applications and potential. For a comprehensive analysis of the techniques and tools of artificial intelligence (AI) and their applications, as well as the future prospects and ethical concerns in pharmacological research and precision medicine, a thorough search was performed using appropriate keywords on PubMed, Google Scholar, and ScienceDirect. The objective was to explore the intersection of AI and precision medicine, which promises to revolutionize healthcare by identifying patient-specific treatments and improving outcomes.

IJARCCE ISSN (O) 2278-1021, ISSN (P) 2319-5940

International Journal of Advanced Research in Computer and Communication Engineering

Impact Factor 8.102 ⁜ Peer-reviewed & Refereed journal ⁜ Vol. 14, Issue 1, January 2025

DOI: 10.17148/IJARCCE.2025.14107

AI techniques, particularly machine learning (ML) and deep learning (DL) have fuelled transformative progress in pharmacological research, overcoming drug development challenges with unmatched momentum, enhanced efficiency, and improved productivity and cost-effectiveness. AI aids in virtual screening, drug design, and drug-target interaction modelling [2]. As a result, AI is applied in various drug discovery stages, including target identification, hit identification, absorption, distribution, metabolism, elimination, toxicity prediction, lead optimization, and drug repositioning [2]. Yet, data availability for robust model training remains a pressing challenge [3]. Ongoing research and advancements aim to overcome challenges and pave the way for a future where AI plays a crucial role in drug discovery and development.

II. REVIEW

Applications of AI in pharmacology

In the application of machine learning, deep learning methods (e.g., convolutional neural network), and natural language processing AI has brought about a groundbreaking transformation in various stages of *drug* discovery, development (including the discovery).

FIGURE 1: Application of artificial intelligence in pharmacological research and precision medicine. Utilizing machine learning, deep learning (CNN) techniques, and natural language processing AI has revolutionized drug discovery and development (discovery phase, clinical trial phase, and post-marketing surveillance) and precision medicine. CNN: convolutional neural networks.



Drug discovery and development

Drug discovery and development are crucial in identifying new therapeutic targets, screening potential lead compounds, and assessing drug efficacy and safety. In recent years, AI has emerged as a powerful tool in these areas, revolutionizing the traditional drug discovery process.

1) AI in Target Identification and Validation

AI revolutionizes target identification and validation in drug discovery, harnessing vast data and computational power. ML and DL algorithms analysed diverse datasets like genomics, proteomics, and clinical data, unveiling promising targets for drug development. The different approaches used in target identification and validation with the help of AI are as follows: (1) statistical analysis-driven approaches - these employ omics data, including genome-wide association studies (GWAS) and summary data-based Mendelian randomization (SMR), to uncover disease-associated candidate target genes [4]. (2) Network-based approaches - network-based methods reveal intricate biological connections. Gene co-expression and miRNA-disease networks identify disease-associated gene sets and miRNA-disease associations within pathways [5]. Target identification utilizes knowledge graphs, which depict graphs containing entities, relationships, and semantic information, to represent and analysed data [6]. (3) Machine learning-based approaches - ML techniques, including classifiers (e.g., random forest, support vector machine, Neural Net) and regression models, are employed to predict whether a gene is a drug target. Additionally, AI models can validate potential targets by predicting their

DOI: 10.17148/IJARCCE.2025.14107

draggability and assessing their suitability for therapeutic intervention [7]. This approach reduces the reliance on experimentally validated hypotheses and enables the exploration of previously unexplored targets.

2) AI-Driven Virtual Screening for Lead Compound Identification

AI revolutionizes virtual screening, expediting compound identification. Models analysed vast chemical databases, predicting compound-target binding likelihood. This prioritizes high-affinity compounds with favourable pharmacokinetic properties efficiently [8-10]. The two main approaches to virtual screening are as follows: (1) structure-based approaches - molecular docking simulations involve a two-step process, conformational space search and scoring. Traditional scoring functions, as well as data-driven machine learning (MLSF) and deep learning-based scoring functions (DLSF), such as 3D convolutional neural Methods include 3D-voxel-based methods (3DCNN) for detecting binding pose patterns and molecular graph-based methods (GCN) for model aggregation. (2) Ligand-based approaches assume compounds with similar structures interact with the same target. They employ quantitative structure-activity relationship (QSAR) models, generating molecular descriptors to describe compounds. ML models predict bioactivity using these descriptors. Ligand-based methods include graph-based models (recurrent neural networks {RNNs}, neural graph fingerprints), sequential models (long short-term memory - a type of RNN for sequential compound representation), and similarity-based models (molecular fingerprints, transcriptomic expressions).

In addition to these approaches, chemogenomic methods combine target proteins and compounds to predict drug-target interactions (DTIs). These methods can be similarity-based, focusing on similarities between proteins and compounds, or feature-based, using fixed-length feature vectors to describe targets and compounds. DL models, such as CNNs and deep belief networks, enhance feature-based methods [8-10].

Evotec, a German biotech company, partnered with Exscientia, a UK-based AI-driven drug discovery company. Using Ex Scientia's "Centaur Chemist" AI design platform, they identified a promising anti-cancer molecule as a drug candidate in just eight months, a fraction of the time traditional methods would require. The AI system analyzed millions of molecules, selecting a few for synthesis, testing, and optimization, leading to the final candidate for clinical trials [11].

3) AI-Guided Lead Optimization

AI-guided lead optimization offers advantages like reduced human bias, continuous modeling of the chemical space, and overcoming data limitations through transfer learning and semi-supervised learning. These approaches hold promise for generating molecules with desirable properties, potentially accelerating drug design timelines. There are several approaches to AI-guided lead optimization which are mentioned as follows: (1) in the recurrent neural networks (RNN)-based approach, deep generative models learn the chemical space distribution and generate new molecules by mastering simplified molecular input line entry system (SMILES) grammar symbol by symbol. Transfer learning and semi-supervised learning address limited target-specific data. (2) Generative autoencoders like variational autoencoders (VAE) and generative adversarial networks (GAN) are used for molecular design. They learn compressed representations in a latent space, with VAEs introducing a probabilistic element. Conditional VAEs incorporate property vectors for conditional design. Semi-supervised VAEs and prototype-driven diversity networks are other variations used in lead optimization. (3) Reinforcement learning (RL) combines deep generative modeling with RL techniques. It maximizes expected return by formulating molecule generation as an accumulation of rewards. Value learning and policy learning are involved, with the design of reward functions being crucial. RL is utilized in de novo molecular design, and specialized generator architectures like differentiable neural computer (DNC) are used for fine-tuning [12-17].

4) AI-Guided Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) Prediction

AI techniques can effectively predict various drug absorption, distribution, metabolism, excretion, and toxicity properties. Predictive models utilize engineered and learned molecular descriptors to accurately forecast human intestinal absorption (HIA). In vitro assays, such as Caco-2 cell permeability and parallel artificial membrane permeability, predict the potential for absorption. Comprehensive datasets enable the development of predictive models for drug-protein binding, P-gp inhibition, and blood-brain barrier (BBB) permeability. By exploring ML models, molecular descriptors, and structural patterns, precise predictions for BBB permeability, cytochrome P450 (CYP) enzyme substrate and inhibitor interactions, plasma half-life, solubility, metabolic stability, potential metabolites, renal excretion, bile salt export pump (BSEP) inhibition, hepatotoxicity assessment, and cardiotoxicity can be achieved [18-29].

5) Prediction of Drug Efficacy and Safety Using AI Models

AI models utilize preclinical and clinical studies data to predict various drug properties. Using ML algorithms, they analyze large datasets and identify molecular features associated with therapeutic response and toxicity, helping select promising drug candidates. Drug-drug interactions are a significant concern in drug development, and accurate prediction of cytochrome P450 (CYP450) enzyme inhibition is crucial. In a study, Wu et al. utilized ensemble learning and DL techniques to classify CYP450 inhibitors [30]. Ensemble models, including random forest, gradient boosting decision

IJARCCE ISSN (O) 2278-1021, ISSN (P) 2319-5940

International Journal of Advanced Research in Computer and Communication Engineering

Impact Factor 8.102 ⁜ Peer-reviewed & Refereed journal ⁜ Vol. 14, Issue 1, January 2025

DOI: 10.17148/IJARCCE.2025.14107

tree, and extreme gradient boosting, outperformed DL, achieving an accuracy of 90.4% [30]. The Shapley Additive explanations (SHAP) method was used to interpret the models and identify potential drug-drug interactions during early drug discovery.

AI-Guided Drug Repositioning

AI-guided drug repositioning involves network-based approaches (clustering, network) and DL algorithms, such as deep neural networks (DNN) and convolutional neural networks (CNN), to identify new indications for existing drugs [31-34]. These computational methods access heterogeneous data and patterns in drug disease associations to prioritize and predict potential drug repositioning candidates. Wu et al. used graph clustering algorithms to identify drug repositioning candidates by constructing a weighted heterogeneous network and considering shared genes for features [35]. Gottlieb et al. constructed a PREDICT classification model using logistic regression and multiple similarity measures to predict drug-disease associations based on ML [36]. Napolitano et al. used gene expression signatures, drug structures, and target proteins to calculate drug similarities and trained a multiclass support vector machines (SVM) model for drug-disease association prediction [37].

III. CLINICAL TRIAL RESEARCH

Protocol Design and Reporting

AI systems extract valuable patterns of information to inform and enhance trial design. The SPIRIT-AI extension provides reporting guidelines for clinical trials evaluating interventions with an AI component [38-40]. These guidelines enhance transparency, consistency, and interpretability by improving protocol reporting and providing evidence-based recommendations for addressing essential elements.

Patient Selection and Recruitment

AI-assisted techniques and digital transformation enable precise patient identification, optimize cohort composition, and enhance recruitment and retention rates in clinical trials. Automation and ML use large datasets, including electronic health records and omics data, to make intelligent predictions and streamline patient selection. This results in improved trial enrolment and retention, ultimately enhancing the efficiency of clinical trials.

Investigator and Site Selection

AI technologies aid in selecting high-functioning investigator sites for clinical trials. They identify target locations, qualified investigators, and priority candidates while ensuring compliance with Good Clinical Practice requirements. AI also helps collect and collate evidence to satisfy regulators regarding study timelines, data quality, and integrity, improving the trial process.

Monitoring and Management of Clinical Trials

AI algorithms analyze real-time patient data, ensuring trial integrity and identifying adverse events.

Automation and ML optimize data collection, improve quality, and enable real-time monitoring for higher trial success rates. AI enhances patient monitoring, medication adherence, and retention through data automation, digital assessments, and real-time insights from wearable technology, enhancing engagement and retention.

Image Analysis and Biomarker Computation

AI techniques enable automated and precise medical imaging analysis, facilitating the identification of patterns, abnormalities, and disease-specific biomarkers. Integrating AI with imaging biomarker analysis pipelines improves image-based evaluations' accuracy, consistency, and efficiency in clinical trials.

Intelligent Data Collection and Management

AI streamlines data collection and management in clinical trials, accelerating the process. Collecting data through automated processes and utilizing this for AI algorithms minimizes errors, extracts relevant information from diverse sources, and data becomes efficiently structured and organized. Real-time access to data enhances analysis and decision-making, expediting trials and improving efficiency [40-42].

Pharmacoepidemiology and pharmacovigilance

AI techniques in pharmacovigilance advance drug safety monitoring by analysing real-world data. Using ML and natural language processing (NLP), AI predicts and detects adverse drug events (ADEs), improving medication-related problem detection from diverse data sources like electronic health records and pharmacovigilance databases. AI also enhances efficiency and consistency in processing individual case safety reports (ICSRs), automating manual processes, removing bias, and providing valuable insights for data scientists and medical professionals. AI-based methods in pharmacovigilance extend beyond data analysis, encompassing adverse event detection, risk assessment, and signal detection during post marketing surveillance. Automation streamlines adverse event case processing, including extraction from source documents and case validity evaluation, improving the efficiency and quality of pharmacovigilance activities [43-48].

In a study, Fan et al. utilize DL techniques and publicly available data to improve the detection and

DOI: 10.17148/IJARCCE.2025.14107

identification of unreported drug side effects. By applying a DL-based approach using Bidirectional Encoder Representations from Transformers (BERT) models on a dataset of 10,000 reviews from WebMD and Drugs.com, the proposed model achieves state-of-the-art performance in ADE detection and extraction. The study showcases the potential of DL in healthcare tasks and information extraction, providing a solution to the challenges doctors face when prescribing drugs [49]. Personalized medicine, driven by advancements in AI and genomic data integration, has revolutionized healthcare by tailoring treatments to individual patients.

AI Models for Predicting Drug Response and Optimizing Treatment Outcomes

AI models optimize treatment outcomes by predicting drug response using ML algorithms and analyzing diverse biomedical data. They identify molecular signatures and phenotypic changes linked to drug response, enabling personalized therapies and drug repurposing. AI models also uncover biological mechanisms of drug response, leading to the development of new therapeutics and targeted interventions. Their use enhances clinical trial success rates and improves drug efficacy and safety predictions.

Integration of Genomic Data and AI Algorithms for Personalized Drug Selection

Integrating genomic data and AI algorithms enables personalized drug selection by analyzing genetic variants associated with drug response and adverse reactions. This approach enhances personalized medicine by avoiding ineffective or harmful medications for specific patients [50,51].

Individualized patient care is crucial in epilepsy treatment, considering that around 30% of epilepsy patients do not achieve sufficient control with available anti-epileptic drugs (AEDs). This leads to challenges such as comorbid illnesses, reduced quality of life, increased mortality risk, and higher treatment costs. A comprehensive understanding and prediction of AED response are needed to overcome these challenges. Previous research has mainly focused on specific genes related to drug metabolism, neglecting other genetic factors and disease mechanisms. However, considering multiple factors, a holistic approach is required in precision medicine. ML techniques can also integrate clinical and genetic data to predict drug response. In a study on brivaracetam, researchers successfully developed predictive models for drug response by combining ML with clinical and genetic data from 235 patients. This study highlights the potential of integrating highdimensional genetics data with clinical information to predict AED response and optimize treatment outcomes [52].

AI-Guided Dosage Optimization for Individual Patients

AI-guided dosage optimization is essential for precision pharmacotherapy. Patient-specific characteristics (age, comorbidities) and data, including clinical information and biomarkers, are analyzed by AI algorithms to determine optimal drug dosages. ML techniques help identify patterns and correlations, enabling personalized dosing regimens for better efficacy and safety.

CURATE.AI is an AI-powered platform for personalized medicine that optimizes treatment outcomes by considering individual patient characteristics. It analyzes patient-specific data, including treatment response and changes in condition, to provide personalized dosing recommendations. The platform dynamically adjusts chemotherapy doses for cancer patients, aiming for optimal efficacy and minimal toxicity. CURATE.AI has potential applications in hypertension, diabetes, and digital therapeutics. The platform harnesses AI to provide tailored dosing recommendations, improving patient care and treatment outcomes 2023 Singh

IV. CONCLUSION

The convergence of artificial intelligence (AI) and machine learning (ML) is revolutionizing drug discovery, offering unprecedented potential to accelerate the development of life-saving therapies. By analyzing vast datasets, these technologies can identify novel drug targets, design and optimize drug candidates, repurpose existing drugs, and personalize treatment plans. AI algorithms can sift through mountains of biological data, such as genetic sequences and protein structures, to pinpoint molecules or pathways involved in disease processes, providing a more targeted approach to drug development. Furthermore, ML models can predict the properties of potential drug molecules, including their binding affinity to target proteins, toxicity, and pharmacokinetic properties, enabling researchers to prioritize promising candidates and refine their design for enhanced efficacy and safety.

REFERENCES

1. “Cloud Computing and Cloud Computing Technologies: A-Review “ in the International Conference on Intelligent Computing & Networking (IC-ICN 2023) by Prof. Vijay Rakhade, miss. Pooja Raju Katore.
2. “Review on 5G Wireless Technology” in the International Conference on Intelligent Computing & Networking (IC-ICN 2023) by Prof. Vijay Rakhade, miss. Achal Thengane.
3. “Communication Between Two Cloud Using Depsky and Program Data Processors System.” in the International Conference on Intelligent Computing & Networking (IC-ICN 2023) by Prof. Vijay Rakhade, Miss. Dharini Pachare.

DOI: 10.17148/IJARCCE.2025.14107

4. “Benefits and Issues of Health Monitoring System Based on the IoT” in the International Conference on Intelligent Computing & Networking (IC-ICN 2023) by Prof. Vijay Rakhade, Mr. Muneshwar Gyaniram Neware.
5. “Big Data Characteristics And Applications” in the International Conference on Intelligent Computing & Networking (IC-ICN 2023) by Prof. Vijay Rakhade, Mr. Harshit Mundra.
6. “Future Farms - Small & Smart: A Review Challenges In Big Data” in the International Conference on Intelligent Computing & Networking (IC-ICN 2023) by Prof. Vijay Rakhade, Mr. Akash A. Howladar.
7. “Internet of Things (IOT): Future Application and Research” in the International Conference on Intelligent Computing & Networking (IC-ICN 2023) by Prof. Vijay Rakhade, Miss. Anuradha Tonge.
8. “Review on study of the Platform for Secure Mobile Application” in the International Conference on Intelligent Computing & Networking (IC-ICN 2023) by Prof. Vijay Rakhade, Miss. Laxmi M. There.
9. “Challenges of Virtualization of Cloud Computing” in the International Conference on Intelligent Computing & Networking (IC-ICN 2023) by Prof. Vijay Rakhade, Miss. Neha Pankaj Rai.
10. “Review On Challenges and Issues in Data Mining” in the International Conference on Intelligent Computing & Networking (IC-ICN 2023) by Prof. Vijay Rakhade, Mr. Omkar K. Khadke.
11. “A Future of Computer Assisted Education” in the International Conference on Intelligent Computing & Networking (IC-ICN 2023) by Prof. Vijay Rakhade, Miss. Roshani D. Karale.
12. “A Research On Digital Image rocessing Technology And Application” in the International Conference on Intelligent Computing & Networking (IC-ICN 2023) by Prof. Vijay Rakhade, Miss. Shweta A. Date.
13. “Review On Security Issues And Challenges In Cloud Computing” in the International Conference on Intelligent Computing & Networking (IC-ICN 2023) by Prof. Vijay Rakhade, Miss. Grishma S. Pise.
14. “Review Paper on Network Security” in the International Conference on Intelligent Computing & Networking (IC-ICN 2023) by Prof. Vijay Rakhade, Miss. Pratiksha Rajurkar.
15. “Security of Cloud Computing” in the International Conference on Intelligent Computing & Networking (IC-ICN 2023) by Prof. Vijay Rakhade, Miss. Achal Jairam Madavi.
16. “A Review on Voice Browser” in the International Conference on Intelligent Computing & Networking (IC-ICN 2023) by Prof. Vijay Rakhade, Mr. Akshay A. Zade.
17. “Smart College Campus Enabled with IoT: For E- Campus Environment” in the International Conference on Intelligent Computing & Networking (IC-ICN 2023) by Prof. Vijay Rakhade, Mr. Bhuvan Nanduji Banpukar.
18. “A Research on use of Manet for Wireless Device” in the International Conference on Intelligent Computing & Networking (IC-ICN 2023) by Prof. Vijay Rakhade, Miss. Sapna K. Titare.
19. “Research on Data Mining” in International Journal of Advanced Research in Computer and Communication Engineering(IJARCCE). By Mr. Chandrakant A. Zade, Prof. Vijay Rakhade, Prof. L. Yadav, ISSN (O) 2278-1021, ISSN (P) 2319-5940.

